INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours.
| Website | http://www.inoviq.com |
| Ticker | ASX:BD1 |
| Revenue | $6 million |
| Employees | 24 (18 on RocketReach) |
| Founded | 2016 |
| Address | 23 Normanby Rd, Notting Hill, Victoria 3168, AU |
| Phone | +61 8 9381 9550 |
| Fax | +61 3 8288 2141 |
| Industry | Biotechnology, Medical Testing & Clinical Laboratories, Health Diagnostics, Healthcare, Health Care, Life Science, Science and Engineering |
| Keywords | Life Sciences, Biotechnology, Biopharma, Research And Development, Pharmaceutical Research, Drug Development, Pharmaceutical, Drug Discovery, Biomedical Research, Therapeutic Development, Precision Medicine, Translational Research, Cancer Research, Molecular Diagnostics, Biomarkers, Oncology, Clinical Trials, Genomics, Healthcare, Proteomics |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325413 Companies, NAICS Code 32 Companies |
Looking for a particular BARD1 Life Sciences Ltd employee's phone or email?
The BARD1 Life Sciences Ltd annual revenue was $6 million in 2026.
Leearne Hinch is the CEO of BARD1 Life Sciences Ltd.
18 people are employed at BARD1 Life Sciences Ltd.
BARD1 Life Sciences Ltd is based in Notting Hill, Victoria.
The NAICS codes for BARD1 Life Sciences Ltd are [325, 3254, 32541, 325413, 32].
The SIC codes for BARD1 Life Sciences Ltd are [28, 283].